×
About 7,320 results

Rituximab, Cyclophosphamide Similar for Inducing EGPA Remission
https://www.medscape.com/viewarticle/963134

Nov 17th, 2021 - Rituximab didn't perform any worse or better at inducing remission after a year in patients with eosinophilic granulomatosis with polyangiitis (EGPA) than did conventional treatment with cyclophosphamide in the phase 3 REOVAS trial conducted in France. Dr Benjamin Terrier The B-cell–depleting agent also had a safety profile similar to cyclophosphamide during that window of time, Benjamin Terrie...

Liver Cancer Risk Lingers Even After HCV Eradication
https://www.medscape.com/viewarticle/963101

Nov 17th, 2021 - Although the risk for liver cancer diminishes for patients with hepatitis C virus (HCV) infections for whom virus is eliminated with direct-acting antiviral (DAA) drugs, these patients are not out of the woods, and those who do not have a sustained viral response (SVR) are at substantially higher risk of developing hepatocellular carcinoma (HCC), results of a large study show. Among the patient...

Exercise Reduces Arm Problems After Breast Cancer Surgery
https://www.medscape.com/viewarticle/963156

Nov 17th, 2021 - Breast cancer treatment often results in shoulder and arm problems, such as chronic pain, restricted shoulder movement, or lymphedema in the armpit area, limiting quality of life and delaying recovery. However, according to a U.K. study published by The BMJ on Nov. 10, women who exercised shortly after having nonreconstructive breast cancer surgery experienced less pain and regained better shou...

Tofacitinib Postmarketing Data Shed Light on JAK Inhibitor Risks
https://www.medscape.com/viewarticle/963183

Nov 17th, 2021 - Additional analyses of a postmarketing trial that was required after the Food and Drug Administration's approval of the Janus kinase inhibitor tofacitinib (Xeljanz, Xeljanz XR) has identified characteristics of older patients with rheumatoid arthritis with at least one cardiovascular risk factor who may be at higher risk for major adverse cardiovascular events (MACE) when taking the drug. Resul...

Children With Cancer and COVID: Most Do Well, Which Ones Don't?
https://www.medscape.com/viewarticle/963049

Nov 16th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. A new study that followed 131 children with cancer who were infected with SARS-CoV-2 shows that most (79%) did well and had only asymptomatic or mild disease. However, others developed severe symptoms; 49 children (37%) were hospitalized, 15 (11%) required admission to the intensive care unit (I...

Increased Risk of Stroke in Cancer Patients and Survivors
https://www.medscape.com/viewarticle/963095

Nov 16th, 2021 - Takeaway A meta-analysis indicates that individuals living with and beyond certain cancers may have an increased risk of stroke. Why this matters Findings suggest that assessment of cardiovascular risk should be a part of cancer survivorship care, with an emphasis on modifying shared cancer/cardiovascular risk factors. Study design UK researchers conducted a meta-analysis of 36 studies, identif...

Association of Circulating IGF-I with Common Non-cancerous Conditions
https://www.medscape.com/viewarticle/963018

Nov 15th, 2021 - Takeaway Circulating insulin-like growth factor-I (IGF-I) was associated with several common conditions (other than cancer), including a positive association with carpal tunnel syndrome and inverse associations with varicose veins and iron deficiency anaemia. Why this matters Higher IGF-I levels have been associated with an increased risk of several cancers in adults without acromegaly, but the...

Confused About COVID-19 Boosters?
https://www.medscape.com/viewarticle/962969

Nov 15th, 2021 - Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. JOHN WHYTE: Are you confused about whether you should get a COVID vaccine booster shot? Let me help try to unpack it for you. Why do some people need boosters? Although COVID-19 vaccination remains effective in preventing severe disease, more and more data suggest vaccination is less effective at preventing in...

Gastric Cancer Prevalent in Hereditary Breast Cancer Patients
https://www.medscape.com/viewarticle/962750

Nov 11th, 2021 - The risk of occult gastric adenocarcinoma is highly prevalent in hereditary lobular breast cancer (HLBC) families who harbor any type of CDH1 variant and this risk remains high in patients with no family history of gastric cancer, a prospective cohort study has shown. "In short, what we are putting forward with these data is that pathogenic/likely pathogenic (P/LP) variants in the CDH1 gene con...

Substantial Declines in Mortality for Most Cancers
https://www.medscape.com/viewarticle/962784

Nov 11th, 2021 - Mortality from cancer has dropped substantially in the United States over the past five decades, according to a new analysis. Researchers found that rates for all cancers combined declined by 27% overall between 1971 and 2019 and decreased significantly for 12 of the 15 top cancer sites analyzed. The data revealed even greater mortality declines for certain cancers in particular years. For exam...

Chemotherapy With FOLFOX Superior to TACE in Liver Cancer
https://www.medscape.com/viewarticle/962798

Nov 11th, 2021 - Hepatic arterial infusion chemotherapy (HAIC) with FOLFOX led to superior patient outcomes and less toxicity than standard of care transarterial chemoembolization (TACE) for patients with large, unresectable hepatocellular carcinoma (HCC), a randomized, phase 3 trial has shown. In a group of 315 patients with unresectable tumors at least 7 cm in diameter and no macrovascular invasion or extrahe...

Ibrutinib Add-on 'Almost Certainly' Saves Lives in DLBCL
https://www.medscape.com/viewarticle/962580

Nov 9th, 2021 - The 3-year event-free survival was 100% when ibrutinib (Imbruvica) was added to standard treatment for two genetic subtypes of diffuse large B-cell lymphoma (DLBCL) among patients age 60 years or younger, according to National Cancer Institute investigators. These patients had either MCD or N1 subtypes of activated B-cell-like (ABC) DLBCL. Both subtypes depend heavily on chronic active B-cell r...

JAK Inhibitors Offer Hope for Hard-to-Treat Atopic Dermatitis but Carry Black-Box Warnings
https://www.medscape.com/viewarticle/962464

Nov 7th, 2021 - Just a few years after the successful launch of dupilumab (Dupixent), new biologics are expanding the treatment arsenal for serious cases of atopic dermatitis. Yet as these topical and oral JAK inhibitors pave the way to more personalized care, safety concerns and screening considerations make it challenging for doctors to discuss these new treatment options with patients. "It's a hard conversa...

New Treatment for Thyroid Cancer Available Through Cancer Drugs Fund
https://www.medscape.com/viewarticle/961944

Nov 5th, 2021 - NICE has published new guidance recommending selpercatinib for use within the Cancer Drugs Fund (CDF), as an option for:  Adults with advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and or lenvatinib, and Adults and adolescents aged 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic th...

Early Detection May Define the Future of Pancreatic Cancer Care
https://www.medscape.com/viewarticle/962171

Nov 5th, 2021 - JOHN WHYTE: Welcome, everyone. I'm Dr. John Whyte, the chief medical officer at WebMD. And you're watching Cancer in Context. Pancreatic cancer: It affects nearly 60,000 people a year. Where are we in terms of advancements and diagnostics? Typically, it's a cancer that's difficult to diagnose. We've had challenges with screening tests. There's been limited treatments. But we have made some prog...

Forming Specialized Immune Cell Structures Could Combat Pancreatic Cancer
https://www.medscape.com/viewarticle/962255

Nov 4th, 2021 - In a new study, researchers stimulated immune cells to assemble into tertiary lymphoid structures that improved the efficacy of chemotherapy in a preclinical model of pancreatic cancer. Overall, the evidence generated by the study supports the notion that induction of tertiary lymphoid structures may potentiate chemotherapy's antitumor activity, at least in a murine model of pancreatic ductal a...

Decades Spent Searching for Genes Linked to Rare Blood Cancer
https://www.medscape.com/viewarticle/962308

Nov 4th, 2021 - Mary Lou McMaster, MD, has spent her entire career at the National Cancer Institute (NCI) searching for the genetic underpinnings that give rise to Waldenstrom's macroglobulinemia (WM). After searching for decades, she has yet to uncover a "smoking gun," though a few tantalizing clues have emerged along the way. "Our questions are pretty basic: Why are some people more susceptible to developing...

Common Diabetes Drug Shrinks Brain Tumors in Mice
https://www.medscape.com/viewarticle/962161

Nov 3rd, 2021 - Many cancers with known genetic causes can be treated by targeting tumors and leaving healthy cells unscathed. But that's not the case for a rare type of brain and spinal cord cancer that primarily strikes children and has no obvious genetic cause. Preliminary testing in mice suggests that the diabetes drug metformin might target these tumors specifically. The drug acts on cell processes that d...

Results With De-escalated Radiotherapy for HPV+ve Oral Cancer
https://www.medscape.com/viewarticle/962174

Nov 3rd, 2021 - CHICAGO — The idea of de-escalating radiotherapy for patients with oropharyngeal squamous cell carcinoma (OPSCC) that is positive for human papilloma virus (HPV) has been debated for a while. Now results from a phase 3 trial (MC1275) show that de-escalated adjuvant radiation therapy (DART) resulted in robust responses and lower toxicity as compared with standard care radiotherapy.   Significant...

New Trials in Leukemia: Could Your Patient Benefit?
https://www.medscape.com/viewarticle/962196

Nov 3rd, 2021 - A number of late-phase clinical trials in leukemia have opened in recent months. Maybe one of your patients could benefit from being enrolled. Adults and Children With Acute or Chronic Leukemias A phase 2 study partnering with the National Marrow Donor Program is seeking individuals aged 1-65 years with lymphoma or one of the following leukemias: "acute leukemia", acute lymphoblastic (ALL), acu...